---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-113549"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:51:21.257223+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cellectar regains Nasdaq compliance after filing restated financials and Form 10-Q

## Summary
- Received Nasdaq letter dated Oct 31, 2024 confirming compliance with Listing Rule 5250(c)(1).
- Filed on Oct 29, 2024 restated audited financials for FY2022 and FY2023 and restated quarterly periods in 2022-2023.
- Also filed restated Q1 2024 quarterly report (Form 10-Q/A) and regular Q2 2024 quarterly report (Form 10-Q).
- Nasdaq noted the matter is now closed, removing delisting risk from late filing.

## SEC filing metadata
- accession: 0001104659-24-113549
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924113549/0001104659-24-113549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924113549/tm2427349d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-113549
- JSON: https://secwatch.observer/filing/0001104659-24-113549.json
- Plain text: https://secwatch.observer/filing/0001104659-24-113549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.